Phase I study of concurrent radiotherapy with TS-1 and vitamin A (TAR Therapy) for head and neck cancer

Torahiko Nakashima, Yuichiro Kuratomi, Tomoya Yamamoto, Muneyuki Masuda, Naoya Hirakawa, Kazumasa Nakamura, Yoshiuki Shioyama, Toshiro Umezaki, Shizuo Komune

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The triple combination of 5-fluorouracil (5-FU), vitamin A and radiation (FAR therapy) has been effectively used to treat head and neck cancer. The biological anti-tumor effect of 5-FU depends on the activity of its metabolizing enzyme, dihydropyrimidine dehydrogenase (DPD). TS-1 is a novel oral DPD inhibitory fluoropyrimidine (DIF). To improve the anti-tumor effect of FAR therapy, we have applied TS-1 in place of 5-FU injection in the combination of Vitamin A and radiation (TAR therapy). In this study, we have examined the appropriate duration of TS-1 medication and the clinical efficacy and safety of TAR therapy. TS-1 was administered orally at a dose of 65 mg/m2 twice a day. Vitamin A (Retinol Palmitate: 50,000 U/day) was administered intra-musculary on each day of radiation. Radiation was given (1.5-2 Gy/day: 5 days/week) for 30-40 Gy. The levels were divided according to the length of TS-1 application as follows: level 1, 2 weeks; level 2, 3 weeks; level 4, 4 weeks. Grade 4 toxicity of anorexia was observed in one case of level 3. We decided that level 2 (3 weeks of TS-1 administration) was the appropriate length of TS-1 application. TAR therapy is a useful concurrent chemo-radiotherapy which might improve the response rate and QOL of patients with HNSCC.

Original languageEnglish
Pages (from-to)803-807
Number of pages5
JournalGan to kagaku ryoho. Cancer & chemotherapy
Volume32
Issue number6
Publication statusPublished - Jun 2005

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase I study of concurrent radiotherapy with TS-1 and vitamin A (TAR Therapy) for head and neck cancer'. Together they form a unique fingerprint.

  • Cite this

    Nakashima, T., Kuratomi, Y., Yamamoto, T., Masuda, M., Hirakawa, N., Nakamura, K., Shioyama, Y., Umezaki, T., & Komune, S. (2005). Phase I study of concurrent radiotherapy with TS-1 and vitamin A (TAR Therapy) for head and neck cancer. Gan to kagaku ryoho. Cancer & chemotherapy, 32(6), 803-807.